Beijing Airdoc Technology (2251) Fundamentals 2026 — Revenue Analysis | SniperIQ
Beijing Airdoc Technology (2251) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of HK$998M, trading at HK$9.88 on the HKSE. This SniperIQ fundamentals page covers Beijing Airdoc Technology's valuation, profitability (net margin -14.4%), revenue (¥173M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Airdoc Technology's market cap?
Beijing Airdoc Technology (2251) has a market capitalization of approximately HK$998M, trading at HK$9.88 on the HKSE. Market cap moves with the live share price.
What is Beijing Airdoc Technology's P/E ratio?
Beijing Airdoc Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Airdoc Technology?
Beijing Airdoc Technology runs a net profit margin of -14.4%, a gross margin of 73.5%, and an operating margin of -21.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Airdoc Technology generate?
Beijing Airdoc Technology reported revenue of ¥173M for fiscal year 2025, with net income of -¥25M and earnings per share (EPS) of -0.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Airdoc Technology pay a dividend?
Beijing Airdoc Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Beijing Airdoc Technology financially healthy?
Beijing Airdoc Technology carries a debt-to-equity ratio of 0.02x and a current ratio of 10.53x, with a market beta of 0.81. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Airdoc Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Airdoc Technology (2251) the key facts are: market cap HK$998M, revenue ¥173M, 52-week range 9.15-16. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Airdoc Technology's full fundamentals live
Get Beijing Airdoc Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.